The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007

Full text for this resource is not available from the Research Repository.

Lichtenberg, Frank R (2013) The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007. European Journal of Health Economics, 14 (1). pp. 41-56. ISSN 1618-7598

Dimensions Badge

Altmetric Badge

Item type Article
URI https://vuir.vu.edu.au/id/eprint/40451
DOI https://doi.org/10.1007/s10198-011-0349-4
Official URL https://link.springer.com/article/10.1007/s10198-0...
Subjects Historical > FOR Classification > 1402 Applied Economics
Historical > FOR Classification > 1605 Policy and Administration
Historical > Faculty/School/Research Centre/Department > College of Business
Keywords orphan diseases; orphan drugs; drug approval; pharmaceutical innovation; econometric model
Citations in Scopus 17 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login